STOCK TITAN

IRD insider Form 4: Code F for 23,795 shares; 319,005 direct

Filing Impact
(Neutral)
Filing Sentiment
(Negative)
Form Type
4

Rhea-AI Filing Summary

Opus Genetics (IRD) reported an insider transaction on a Form 4. On 10/22/2025, a transaction in Common Stock with code F involved 23,795 shares at $1.95. After this activity, the reporting person beneficially owns 319,005 shares, held directly.

The reporting person is listed as a Director and Officer (President), and the filing was made by one reporting person.

Positive

  • None.

Negative

  • None.
Insider YERXA BENJAMIN R
Role President
Type Security Shares Price Value
Tax Withholding Common Stock 23,795 $1.95 $46K
Holdings After Transaction: Common Stock — 319,005 shares (Direct)
Footnotes (1)
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
YERXA BENJAMIN R

(Last) (First) (Middle)
C/O OPUS GENETICS, INC.
8 DAVIS DRIVE, SUITE 220

(Street)
DURHAM NC 27713

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Opus Genetics, Inc. [ IRD ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
X Officer (give title below) Other (specify below)
President
3. Date of Earliest Transaction (Month/Day/Year)
10/22/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 10/22/2025 F 23,795 D $1.95 319,005 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
/s/ Amy Rabourn, by Power of Attorney 10/24/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Opus Genetics (IRD) disclose in this Form 4?

An insider reported a transaction in Common Stock on 10/22/2025 with code F, covering 23,795 shares at $1.95.

How many Opus Genetics shares are beneficially owned after the transaction?

The reporting person beneficially owns 319,005 shares, held directly.

What roles does the reporting person hold at Opus Genetics (IRD)?

The reporting person is identified as a Director and an Officer (President).

What was the transaction date and price per share?

The date was 10/22/2025 and the reported price per share was $1.95.

How many reporting persons filed this Form 4 for IRD?

It was filed by one reporting person.

What is the ownership form after the transaction?

Ownership is listed as Direct (D).